EICHOR
● Terminated
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
Condition: Melanoma · Non Small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Sponsor: UNICANCER
About this study
This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (19)
| Institut Bergonie | Bordeaux, France | — |
| Centre Hospitalier de Caen | Caen, France | — |
| Centre Jean Perrin | Clermont-Ferrand, France | — |
| Centre Hospitalier Inter. de Creteil | Créteil, France | — |
| Centre Georges François Leclerc | Dijon, France | — |
| Centre Oscar lambret | Lille, France | — |
| Centre Léon Bérard | Lyon, France | — |
| Institut Régional du Cancer de Montpellier | Montpellier, France | — |
| Institut de cancérologie de l'ouest | Nantes, France | — |
| Centre Antoine Lacassagne | Nice, France | — |
| Institut Curie | Paris, France | — |
| Institut Jean Godinot | Reims, France | — |
+ 7 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03412058